Company release
23:00 Finnish time / 22:00 Swedish time
The Board of Directors of
The Board of Directors of Nanoform has on
There is a weighty financial reason from the company's point of view to issue stock options as provided in Chapter 10, Section 1 of the Finnish Limited Liability Companies Act, because the stock options are issued in order to commit company's personnel to the company.
The option program was open for participation by all employees at Nanoform. The total number of option rights to be issued is at most 1,240,412. The stock options entitle to subscribe for at most 1,240,412 shares in Nanoform. Each stock option entitles to subscribe for one new share. The subscription price for shares subscribed with stock options is
The theoretical market value of the program is estimated at approximately
The subscription period for shares based on the option rights shall commence from the registration of stock options to the
The stock options entitle to subscribe for shares during the subscription period in accordance with the subscription schedule agreed in the option agreement between Nanoform and each option holder so that all issued stock options may be exercised to subscribe for shares at the latest on
For further information, please contact:
Albert Haeggström, CFO
albert.haeggstrom@nanoform.com
+358 29 370 0150
For investor relations queries, please contact:
hvh@nanoform.com
+46 7686 650 11
About Nanoform
Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform's platform technologies. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services. Nanoform's capabilities include GMP manufacturing, and its services span the small to large molecule development space with a focus on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in
https://news.cision.com/nanoform/r/the-board-of-directors-of-nanoform-finland-plc-decided-on-issue-of-stock-options-under-an-option-pro,c3907219
https://mb.cision.com/Main/18905/3907219/2533498.pdf
(c) 2024 Cision. All rights reserved., source